Redesign Science Secures Multi-Million Dollar Funding to Advance AI-Driven Small Molecule Drug Discovery

VCBeat (WeChat ID: vcbeat) has learned that Redesign Science, an AI platform technology company for drug development, has announced the completion of a multi-million-dollar financing round. The round was led by Notation Capital, with participation from Morningside Ventures, Third Kind Venture Capital, and Refactor Capital, among others. Qingtong Capital facilitated the successful completion of this financing round. The funds will help Redesign Science achieve its long-term strategic development plans. Redesign Science plans to expand its scientific and engineering teams to deploy its cloud computing platform, enhancing the platform’s scalability and automation.

Redesign Science, founded in New York, USA, in 2017, specializes in accelerating early-stage small-molecule drug discovery through innovative technologies. By leveraging powerful cloud-based parallel molecular dynamics simulations, Redesign Science focuses on protein targets that are traditionally considered undruggable. In conventional computational chemistry, the development of diverse small-molecule drugs against these protein targets has been hindered by a lack of sufficient data.

It is reported that the AlphaSpace physics engine, developed on Redesign Science’s proprietary technology platform, enables ultra-long-timescale molecular dynamics simulations of drug target proteins with atomic-level precision, facilitating rapid screening of small-molecule databases containing hundreds of millions of compounds. By integrating classical mechanics and quantum mechanics, Redesign Science can perform rapid, high-precision modeling of any protein target, even those lacking structural data.

Furthermore, the Redesign Science platform delivers highly scalable services through cloud-based deployment, ensuring the rapid, concurrent execution of any number of research projects. This approach reduces the dependency on target protein structures and experimental data in drug development, thereby accelerating the R&D process for novel small-molecule drugs targeting new indications. Currently, Redesign Science has established multiple collaborative partnerships for new drug development, focusing on therapeutic areas including cancer and inflammatory bowel disease (IBD).

Through collaborative research on a variety of diseases with its partners, Redesign Science plans to leverage its AlphaSpace physics engine to uncover previously unknown protein mechanisms and develop novel small-molecule drugs for disease treatment. Highlighting the importance of these partnerships, Founder and CTO Li Haotian explained, “In the past, biopharmaceutical companies often struggled to advance small-molecule development projects after identifying new targets due to a lack of data. Now, by simulating novel proteins using physical models, Redesign Science helps our partners rapidly understand protein mechanisms and develop new types of drugs that were previously difficult to obtain.”

“We are at a critical juncture in drug discovery. While our understanding of biological systems and capabilities in high-performance computing have advanced significantly, the promises of past rational drug design efforts remain unfulfilled. Redesign Science aims to deliver on these promises through its technology platform, working alongside partners to accelerate the development of new drugs,” said David Rooklin, Founding Partner and CEO.

Jing Xutian, Vice President of Morningside Ventures, stated: “In recent years, the substantial increase in computing power and the significant reduction in cloud computing costs have brought varying degrees of change to various industries. For a previously niche field—molecular dynamics-driven drug discovery—these advancements may have triggered a qualitative leap resulting from quantitative accumulation. They have made it possible to observe the motion of drug targets within meaningful timeframes, thereby facilitating the discovery of small-molecule compounds that can bind to non-traditional crystalline conformations. Redesign Science has fully leveraged this technological variable by combining its proprietary expertise in molecular dynamics algorithms with efficient engineering implementation, which will greatly enhance the likelihood of discovering novel blockbuster small-molecule drugs.”

Gu Jianlu, Managing Director at Qingtong Capital, stated, “Traditional drug development is currently facing numerous challenges, including high capital requirements, lengthy cycles, and elevated costs. The pace of new drug development lags far behind the rate at which novel drug targets are discovered, significantly limiting the potential for developing a diverse range of innovative therapies. The integration of artificial intelligence (AI) undoubtedly represents a critical breakthrough for future drug discovery. Redesign Science has pioneered the industry’s first molecular dynamics-based drug design platform. Leveraging advanced protein modeling algorithms, it precisely identifies more small-molecule targets with strong druggability potential. We are highly optimistic about Redesign Science’s future growth, and Qingtong Capital will continue to focus closely on the major trend of AI-driven drug development.”